DiviTum TKa can be used as a non-invasive biomarker to assess the presence of actively proliferating disease, monitor response to treatment, and detect potential early disease recurrence in adjuvant breast cancer patients.
References:
Williams A, Bear H, Denkert C, et al. “Evaluation of proliferation biomarker serum thymidine kinase activity and prediction of early relapse in HR positive HER2 negative high risk early breast cancer: Analysis from the PENELOPE-B trial” San Antonio Breast Cancer Symposium 2024, Poster P1-09-06.
Witkiewicz A, Schultz S, Knudsen ES et al. “Interrogating serum thymidine kinase activity with CDK4/6 inhibitor based therapies: real-world experience in the metastatic and adjuvant setting” San Antonio Breast Cancer Symposium 2024, Poster P2-05-16.
